HUTCHMED (China) Limited is a biopharmaceutical firm dedicated to the discovery, advancement, and marketing of innovative targeted and immune-based treatments for various ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $0.24 · Revenue $611.09M · 4 analysts
Est. EPS $-0.52 · Revenue $307.93M · 1 analysts
Est. EPS $-0.55 · Revenue $318.48M · 1 analysts
Est. EPS $-0.39 · Revenue $319.35M · 1 analysts
EPS $0.05 · Revenue $139.14M
EPS $0.05 · Revenue $139.14M
EPS $2.60 · Revenue $549.96M
EPS $0.01 · Revenue $135.42M
EPS $1.30 · Revenue $138.84M
EPS $1.30 · Revenue $138.84M
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $550.0M | -12.7% | 0.0% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $458.1M | +1114.2% | 0.0% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +38.7% | -13.7% | 0.0% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -10.0% | -43.5% | 0.0% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | +83.3% | +1291.4% | 0.0% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-88.8M | -409.3% | 0.0% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -16.1% | -483.6% | 0.0% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 7.9% | -33.1% | 0.0% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 4.96x | +75.2% | 0.0% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $1.8B | +37.6% | 0.0% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | 2.60 vs 2.69 | -3.3% | 0.05 vs -0.52 | +108.8% |
| Revenue Surprise | $550.0M vs $563.7M | -2.4% | $139.1M vs $307.9M | -54.8% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| May 20, 2026 | Cheng Chig Fung | director, officer: Acting CEO and CFO | Long Term Incentive Plan awards granted on Aug 5, 2024 | A | 30,157 | — |
| May 20, 2026 | Cheng Chig Fung | director, officer: Acting CEO and CFO | Long Term Incentive Plan awards granted on Jun 9, 2025 | A | 26,307 | — |
| May 20, 2026 | Nixon Charles George Rupert | officer: Group General Counsel | Long Term Incentive Plan awards granted on Jun 9, 2025 | A | 7,644 | — |
| May 20, 2026 | Nixon Charles George Rupert | officer: Group General Counsel | Long Term Incentive Plan awards granted on Aug 5, 2024 | A | 7,445 | — |
| May 20, 2026 | Su Wei-guo | director, officer: CEO and CSO | Long Term Incentive Plan awards granted on Aug 5, 2024 | A | 132,864 | — |
David Ng: Hello, everyone. Welcome to HUTCHMED 2025 Full Year Results and Business Update. Today, we're going to go through our results in a formal presentation by our senior management, and then it will be followed by Q&A. My name is David. I'm the Head of IR of HUTCHMED. We are very happy that we're going to have our senior management to present the results. Let me hand off the time to our acting Chief Executive Officer and Chief Financial Officer, Johnny Cheng. Johnny? Johnny Cheng: Thank you, David, and thank you, everyone, for attending HUTCHMED's 2025 results webcast. Joining me today is our Deputy CFO, Lorenso Chiu, who will give us an overview of our financial performance. Our Head of Commercial, George Yuan, who will share with you our commercial performance. And our Head of Discovery, Dr. Guangxiu Dai, who will provide an update on our R&D pipeline progress. A quick highlight of our 2025 achievements. We are pleased with our ex-China FRUZAQLA sales, which had 26% growth versus last year, resulting in $366 million in in-market sales. FRUZAQLA has now rolled out to over 38 countries. As for our China sales, it has rebounded in the second half of the year, achieving 21% in-market sales growth versus our first half interim results. In terms of our cash position, we have about $1.4 billion, which allows us to accelerate our global ATTC development and provide resources to explore potential in-licensing and M&A opportunities. We have now advanced 2 of our ATTC programs into the clinic, which we believe will have huge market potential. In addition, we are pursuing potential business development opportunities with multinational companies. I will now turn it over to Lorenso for the financial review and outlook. Lorenso Chiu: Yes. Thanks, Johnny. Let me give an overview of our key financial highlights for 2025. Total oncology revenue was $286 million. This includes $71 million R&D-related upfront and milestone revenues. For oncology products revenue, there was a rebound from our China oncology products, which recorded 21% growth in in-market sales in the second half, while FRUZAQLA continues its global expansion. On net income, we recorded a profit of $457 million for 2025, mainly due to the SHPL divestment gain of $416 million. Excluding this onetime gain, our core operations remain profitable. Our R&D expenses for 2025 were $148 million. Expenses were lower versus 2024 as many of our late-stage trials are in the completion stage with multiple NDAs now awaiting approvals. In addition, we began shifting our investments into our early-stage ATTC assets with 2 candidates already in the clinic. Our cash position has been further strengthened to about $1.4 billion. That positions us well to accelerate both investments and developments of our ATTC programs. Looking forward to 2026, our oncology revenue guidance is in the range of $330 million to $450 million. This reflects solid growth from 2025, driven by strong growth in our China commercial …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Weiguo Su | Chief Executive Officer, Chief Scientific Officer & Executive Director (Leave of Absence) | USD 1,751,283 | — | 1959 | Active |
Chig Fung Cheng | Acting Chief Executive Officer, Chief Financial Officer & Executive Director | USD 1,158,008 | Male | 1967 | Active |
Thomas Fu | Senior Vice President of Global Quality | — | — | — | Active |
Xinhui Hu | Executive Vice President & Chief Technical Officer | — | — | 1973 | Active |
Charles George Rupert Nixon | Group General Counsel | — | Male | 1970 | Active |
Kin Hung Lee | Senior Vice President of Corporate Management & Communications | — | Male | 1977 | Active |
Yiling Cui | Executive Vice President & Head of Operations | — | Female | — | Active |
David Ng | Head of Investor Relations & Capital Strategies | — | Male | — | Active |
Qingmei Wang | Executive Vice President of Business Development & Strategic Alliances | — | — | 1963 | Active |
Selina Zhang | Senior Vice President of Global Human Resources | — | Female | — | Active |
HUTCHMED NASDAQ: HCM said it has entered a co-development and licensing agreement with GSK for ex-China rights to HMPL-A830, a preclinical KRAS-EGFR antibody-targeted therapy conjugate, or ATTC. The transaction has a total potential value of approximately $1.3 billion, including a $110 million upfront payment, according to Acting Chief Executive Officer and Chief Financial Officer Johnny Cheng.
HUTCHMED (China) Limited (HCM) Discusses Strategic Partnership With GSK and Licensing of Oncology Asset A830 Transcript
Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) won ringing endorsements from City brokers on Thursday after securing a blockbuster licensing agreement with GSK PLC (LSE:GSK, NYSE:GSK), exposing what analysts regard as a deep valuation disconnect. The shares leapt 15% to 205.84p as Cavendish and Panmure Liberum reiterated their respective 'buy' ratings, arguing that the market continues to overlook the biotech's expanding oncology pipeline.
Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) shares jumped 17% to 210p on Thursday after the oncology specialist struck a licensing agreement with GSK worth up to US$1.295 billion for its experimental KRAS-EGFR cancer therapy. The shares were up 30.5p from Wednesday's 179.5p close following news that GSK will receive exclusive rights outside Mainland China, Hong Kong, Macau and Taiwan to develop and commercialise HMPL-A830.
GSK subsidiary GlaxoSmithKline Intellectual Property (No. 4) Ltd will pay a unit of HUTCHMED (China) $110 million upfront for rights to an experimental drug for solid tumours, the Chinese drugmaker said on Thursday.
